Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring

Acta Ophthalmologica

Volumn 89, Issue 4, 2011, Pages

  Hermann, Manuel Marcel ^a   Papaconstantinou, Dimitris ^b   Muether, Philipp Sebastian ^a   Georgopoulos, Gerasimos ^b   Diestelhorst, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

brimonidine; compliance; glaucoma; medication adherence; monitoring

Indexed keywords

BRIMONIDINE; PROMETHAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MONITOR; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUINOXALINES; VISUAL ACUITY;

EID: 79958173559     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02050.x     Document Type: Article

References (32)

1. Ajit RR, Fenerty CH, &, Henson DB, (2010): Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid. Eye (Lond) 24: 1338-1343.
2. Anderson DR, (2003): Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 14: 86-90. (Pubitemid 36584227)
3. Boden C, Sit A, &, Weinreb RN, (2006): Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops. J Glaucoma 15: 30-34. (Pubitemid 43068417)
4. Buchan JC, Siddiqui S, &, Gilmour D, (2007): Once daily drop regimes help reduce involuntary non-compliance. Graefes Arch Clin Exp Ophthalmol 245: 327-328.
5. Cohen J, (1988): Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum.
6. Diestelhorst M, Hellmich M, Hochrainer D, Roessler G, Steinfeld A, &, Zierenberg B, (2005): The microspray: a new ocular drug delivery device. Invest Ophthalmol Vis Sci 46: ARVO E-Abstract 2469.
7. Ersoy L, Hermann MM, &, Diestelhorst M, (2010): A new reminder system improves adherence with topical ocular therapy significantly. Invest Ophthalmol Vis Sci 51: ARVO E-Abstract 181.
8. Friedman DS, Nordstrom B, Mozaffari E, &, Quigley HA, (2005): Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology 112: 1500-1504. (Pubitemid 41725403)
9. Friedman DS, Quigley HA, Gelb L, et al., (2007): Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 48: 5052-5057. (Pubitemid 351260915)
10. Friedman DS, Okeke CO, Jampel HD, Ying GS, Plyler RJ, Jiang Y, &, Quigley HA, (2009): Risk factors for poor adherence to eye drops in electronically monitored patients with glaucoma. Ophthalmology 116: 1097-1105.
11. Gruner K, Suverkrup R, &, Diestelhorst M, (2009): Latanoprost Ophthalmic Lyophilizate Carrier Systems (OLCS). Invest Ophthalmol Vis Sci 50: ARVO E-Abstract 5555.
12. Hahn SR, Friedman DS, Quigley HA, Kotak S, Kim E, Onofrey M, Eagan C, &, Mardekian J, (2010): Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma. Ophthalmology 117: 1339-1347.
13. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, &, Hussein M, (2002): Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 120: 1268-1279. (Pubitemid 36105431)
14. Hermann MM, &, Diestelhorst M, (2006): Microprocessor controlled compliance monitor for eye drop medication. Br J Ophthalmol 90: 830-832. (Pubitemid 43973989)
15. Ho LY, Camejo L, Kahook MY, &, Noecker R, (2008): Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid. Clin Ophthalmol 2: 769-772.
16. Kass MA, Meltzer DW, Gordon M, Cooper D, &, Goldberg J, (1986): Compliance with topical pilocarpine treatment. Am J Ophthalmol 101: 515-523. (Pubitemid 16114195)
17. Kass MA, Gordon M, Morley RE Jr, Meltzer DW, &, Goldberg JJ, (1987): Compliance with topical timolol treatment. Am J Ophthalmol 103: 188-193. (Pubitemid 17005483)
18. Kass MA, Heuer DK, Higginbotham EJ, et al., (2002): The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701-713. (Pubitemid 34620348)
19. Kooner KS, Albdoor M, Cho BJ, &, Adams-Huet B, (2008): Risk factors for progression to blindness in high tension primary open angle glaucoma: comparison of blind and nonblind subjects. Clin Ophthalmol 2: 757-762.
20. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, &, Walker AM, (2005): Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 140: 598-606.
21. Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, &, Friedman DS, (2009): Adherence with topical glaucoma medication monitored electronically the travatan dosing aid study. Ophthalmology 116: 191-199.
22. Rait JL, &, Adena MA, (2007): Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. Clin Experiment Ophthalmol 35: 602-611. (Pubitemid 47491216)
23. Reardon G, Schwartz GF, &, Mozaffari E, (2003): Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 13 (Suppl. 4): S44-S52.
24. Robin AL, Novack GD, Covert DW, Crockett RS, &, Marcic TS, (2007): Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 144: 533-540.
25. Rossi GC, Pasinetti GM, Scudeller L, Tinelli C, Milano G, &, Bianchi PE, (2010): Monitoring adherence rates in glaucoma patients using the travatan dosing aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother 11: 499-504.
26. Schwartz GF, (2005): Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 16: 114-121. (Pubitemid 43790804)
27. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, &, Svarstad B, (2006): Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 113: 431-436.
28. The AGIS Investigators (2000): The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 130: 429-440.
29. Tsai JC, (2006): Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol 17: 190-195. (Pubitemid 43790816)
30. Tsai JC, McClure CA, Ramos SE, Schlundt DG, &, Pichert JW, (2003): Compliance barriers in glaucoma: a systematic classification. J Glaucoma 12: 393-398. (Pubitemid 37237370)
31. Wilensky J, Fiscella RG, Carlson AM, Morris LS, &, Walt J, (2006): Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 141: S28-S33. (Pubitemid 43028477)
32. World Medical Association (2008): Declaration of Helsinki (October 2008). (accessed November 4, 2010).